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Abstract
Background: Dark chocolate and flavanol-rich cocoa products have attracted interest as an alternative treatment
option for hypertension, a known risk factor for cardiovascular disease. Previous meta-analyses concluded that
cocoa-rich foods may reduce blood pressure. Recently, several additional trials have been conducted with
conflicting results. Our study summarises current evidence on the effect of flavanol-rich cocoa products on blood
pressure in hypertensive and normotensive individuals.
Methods: We searched Medline, Cochrane and international trial registries between 1955 and 2009 for randomised
controlled trials investigating the effect of cocoa as food or drink compared with placebo on systolic and diastolic
blood pressure (SBP/DBP) for a minimum duration of 2 weeks. We conducted random effects meta-analysis of all
studies fitting the inclusion criteria, as well as subgroup analysis by baseline blood pressure (hypertensive/
normotensive). Meta-regression analysis explored the association between type of treatment, dosage, duration or
baseline blood pressure and blood pressure outcome. Statistical significance was set at P < 0.05.
Results: Fifteen trial arms of 13 assessed studies met the inclusion criteria. Pooled meta-analysis of all trials
revealed a significant blood pressure-reducing effect of cocoa-chocolate compared with control (mean BP change
± SE: SBP: -3.2 ± 1.9 mmHg, P = 0.001; DBP: -2.0 ± 1.3 mmHg, P = 0.003). However, subgroup meta-analysis was
significant only for the hypertensive or prehypertensive subgroups (SBP: -5.0 ± 3.0 mmHg; P = 0.0009; DBP: -2.7 ±
2.2 mm Hg, P = 0.01), while BP was not significantly reduced in the normotensive subgroups (SBP: -1.6 ± 2.3
mmHg, P = 0.17; DBP: -1.3 ± 1.6 mmHg, P = 0.12). Nine trials used chocolate containing 50% to 70% cocoa
compared with white chocolate or other cocoa-free controls, while six trials compared high- with low-flavanol
cocoa products. Daily flavanol dosages ranged from 30 mg to 1000 mg in the active treatment groups, and
interventions ran for 2 to 18 weeks. Meta-regression analysis found study design and type of control to be
borderline significant but possibly indirect predictors for blood pressure outcome.
Conclusion: Our meta-analysis suggests that dark chocolate is superior to placebo in reducing systolic
hypertension or diastolic prehypertension. Flavanol-rich chocolate did not significantly reduce mean blood pressure
below 140 mmHg systolic or 80 mmHg diastolic.
Background
Flavanol-rich chocolate and cocoa products have attracted
interest as nonpharmacological treatment options for high
blood pressure, a known risk factor for cardiovascular dis-
ease [1,2]. Even small reductions in blood pressure sub-
stantially reduce cardiovascular risk [3,4]. Current
guidelines strongly recommend integration of lifestyle
modification and complementary treatment with the use
of conventional blood pressure medications [5].
Polyphenols, in particular flavanols in cocoa products,
have been shown to increase the formation of endothe-
lial nitric oxide, which promotes vasodilation and conse-
quently may lower blood pressure [6-8]. Meta-analyses
by Taubert et al. (2007) [9], including five small trials
[10-13], and Desch et al. (2010) [14], including 10 trials
[10-13,15-20], concluded that cocoa-rich foods may
reduce blood pressure. However, additional trials have
been published since then, with conflicting results
[21-24]. Our study updates current research on the
effect of cocoa-rich products taken daily for two or
more weeks compared with placebo on blood pressure
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any medium, provided the original work is properly cited.in adults. In addition, we explored the influence of base-
line blood pressure, dosage, duration, type of control,
study design, age, body mass index and trial quality on
blood pressure outcome.
Methods
Search strategy
We searched the Medline and Cochrane databases for
randomised controlled trials of chocolate or cocoa on
blood pressure published between 1955 and 2009 using
the following search terms: chocolate OR cocoa AND
blood pressure. We also searched reference lists of pub-
lished studies and checked international trial registries
http://www.clinicaltrials.gov; http://www.trialregister.nl;
http://www.anzctr.org.au; http://www.controlled-trials.
com for unpublished but completed studies investigating
chocolate/cocoa for blood pressure.
Selection of trials
Trials were included in the meta-analysis if the control
group received a placebo or a low dose of flavanol-
containing cocoa product (drink, bar or tablet), the trial
duration was ≥ 14 days, and the clinical mean or median
systolic or diastolic blood pressure (SBP/DBP) and stan-
dard deviation (SD) were available. We contacted
authors of studies which did not report numerical mean
SBP/DBP or SD and received datasets from two studies
[18,22], which we included in the meta-analysis. Three
eligible completed but unpublished studies were
excluded because data were not available at the time of
this study [25-27].
Data extraction and quality assessment
Data were abstracted and quality was assessed indepen-
dently by two investigators (KR, PF) using guidelines
published by the Cochrane Collaboration [28] (Tables
1,2,3). Any disagreement was resolved by discussion
between the authors (KR, PF) in consultation with the
statistician (TS). Characteristics of trials included in the
meta-regression analysis are shown in Table 1. We
assessed quality on the basis of randomisation, blinding,
whether blood pressure was a primary outcome mea-
sure, loss to follow-up, funding source and whether
compliance and dietary chocolate intake had been
assessed, as these could have influenced findings (Table
3). No trial was excluded in the meta-analysis on
grounds of quality; however, higher-quality trials (score
≥ 3.5 of 5 points) were compared with lower-quality
trials by meta-regression analysis.
Analysis
Meta-analysis was conductedu s i n gt h eC o c h r a n eP r o -
gram Review Manager version 5 [29]. Owing to high
heterogeneity between trials, we used a random effects
model and considered subgroup meta-analysis by base-
line mean blood pressure, similar to our recent meta-
analysis of the effect of garlic on blood pressure [30].
For systolic blood pressure, trials were divided into a
hypertensive subgroup (SBP ≥ 140 mmHg) and a nor-
motensive subgroup (SBP < 140 mmHg) at the start of
treatment. For diastolic blood pressure, a division into a
higher BP subgroup (DBP ≥ 80 mmHg) and lower BP
subgroup (DBP < 80 mmHg) at the start of treatment
allowed an even distribution of trials between subgroups
and reduction in heterogeneity.
Meta-regression analyses were conducted using Stata
version 10 [31] to explore reasons for high heterogeneity
in the pooled meta-analysis of all studies. The following
variables were tested, as their associations with blood
pressure outcomes are physiologically plausible: Dosage
of polyphenols in the active treatment group
(continuous variable), type of control (categorical vari-
able: low-flavanol control as drink, tablet or bar/
flavanol-free control as white chocolate, milk, or placebo
capsules), duration (continuous and categorical > 2
weeks yes/no), study design (parallel versus crossover),
starting SBP (continuous and categorical > 140 mmHg
yes/no), starting DBP (continuous and categorical >80
mmHg yes/no), quality score (≥ 3.5 yes/no), average
body mass index (BMI) (continuous and categorical >
25 or > 30 yes/no) and average age (continuous).
If meta-regression results indicated a variable to con-
tribute significantly to heterogeneity between studies,
subgroup analysis by this variable was conducted, testing
whether there was an effect of treatment on blood pres-
sure outcomes within each subgroup. If heterogeneity
was reduced, the subgroup analysis provided a more
reliable estimate of pooled effect size between the treat-
ment groups. Additionally, sensitivity analysis excluding
selected trials explored the robustness of results. Publi-
cation bias or small study effect was assessed by Begg’s
funnel plots and Egger’s regression tests [32,33].
Results
Summary of included studies
A total of 18 publications including 21 trial arms were
assessed in detail for inclusion [10-13,15-24,34-38]
(Figure 1). Fifteen trial arms reported in 13 publications
met the inclusion criteria [10-13,15-18,20-24] (Figure 1,
Table 1). Six trial arms were excluded because 1) the
same population and protocol were used in [19] com-
pared with [13]; 2) the comparison group received other
vasoactive substances rather than placebos as a) choco-
late ± plant sterols [34,35], b) tomato extract in phase 2
of trial [23], or c) half dose of chocolate [38]; 3) mean
SBP/DBP and SD were not reported and could not be
obtained from the authors [36]; and 4) the trial was of
1-day duration [37] (Table 2).
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Trial; Location Study design;
treatment/control
groups
Dosage;
duration
Active
ingredients per
daily dosage
Mean
age;
mean
BMI
N
treatment/
control
Mean SBP (SD) in
mmHg at start/end of
treatment versus
control
Mean DBP (SD) in
mmHg at start/end of
treatment versus
control
Taubert et al.
[10]; Germany
Crossover
a,b 100 g/d; 500 mg
polyphenols
59.5 yr; 13/13 Cocoa: 153.4 (4.4)/148.6
(2.4);
Cocoa: 84.5 (4.6)/82.9
(4.6);
Dark/white
chocolate
14 d 24.1 Control: 153.6 (4.4)/
154.0 (3.6)
Control: 84.2 (4.2)/84.5
(4.3)
Murphy et al.
[15]; Australia
Parallel; 6 tablets/d 234 mg
flavanols;
43.5 yr; 13/15 Cocoa: 118 (13)/120
(12);
Cocoa: 78 (12)/77 (10);
High/low flavanol
cocoa tablets
28 d Control: 6.4 mg 26.0 Control: 116 (9)/119 (8) Control: 76 (8)/76 (7)
Engler [11];
USA
Parallel; 46 g/d; 213 mg
procyanidins
32.1 yr; 11/10 Cocoa: 121 (17.9)/120
(13.3)
Cocoa: 68.1 (8.3)/69
(6.6)
High/low flavanoid
chocolate
14 d 22.6 Control: 112.8 (8.9)/110
(6.3)
Control: 66.1 (5.4)/66
(6.3)
Fraga et al.
[12]; USA
Crossover
a; 105 g/d; 168 mg
flavanols
18.0 yr; 27/28 Cocoa: 123 (11.2)/117
(7.5)
Cocoa: 72 (7.5)/67 (7.5)
Dark/white
chocolate
14 d 24.1 Control: 123 (11.2)/121
(7.5)
Control: 71 (7.5)/70 (7.5)
Grassi
(normotensive
arm) [13]; Italy
Crossover
a,b; 100 g/d; 500 mg
polyphenols
33.9 yr; 15/15 Cocoa: 112.9 (8.5)/105.9
(6.6)
Cocoa: 74.0 (5.7)/69.8
(4.5)
Dark/white
chocolate
15 d 22.6 Control: 113.2 (7.9)/
112.7 (7.6)
Control: 73.8 (5.5)/73.5
(5.3)
Grassi et al.
(hypertensive
arm [13]; Italy
Crossover
a,b; 100 g/d; 500 mg
polyphenols
43.7 yr; 20/20 Cocoa: 141.3 (4.8)/129.3
(5.7);
Cocoa: 92.4 (3.8)/84.6
(5.6);
Dark/white
chocolate
15 d 25.4 Control: 141.1 (5.4)/
140.4 (4.6)
Control: 91.8 (4.7)/91.2
(4.7)
Taubert et al.
[16]; Germany
Parallel
a; 6.3 g/d; 30 mg
polyphenols
63.6 yr; 22/22 Cocoa: 147.7 (7.1)/144.8
(ng);
Cocoa: 86.4 (4.1)/84.5
(ng);
Dark/white
chocolate
126 d (18 wk) 24.0 Control: 147.5 (8.0)/
147.6 (ng)
Control: 86.7 (3.8)/86.7
(n.g.)
Crews et al.
[17]; USA
Parallel
a; 37 g/d choc +
11 g/d drink;
754 mg
proanthocyanins;
68.8 yr; 45/45 Cocoa: 126.8 (14.3)/
123.3 (12.3);
Cocoa: 74.2 (8.2)/73.7
(7.5);
Dark chocolate +
cocoa drink/low
flavanol chocolate +
drink
42 d (6 wk) Control: 41.1 mg 25.3 Control: 128.6 (14.3)/
125.5 (12.7)
Control: 75.0 (8.0)/74.4
(7.7)
Grassi et al.
[18]; Italy
Crossover
a,b; 100 g/d; 1008 mg
phenols
44.8 yr; 19/19 Cocoa: 141.1 (3.4)/137.3
(4.0);
Cocoa: 91.2 (4.2)/87.3
(4.6);
Dark/white
chocolate
15 d 26.5 Control: 140.9 (3.4)/
140.8 (3.5)
Control: 91.1 (3.7)/90.9
(3.5)
Muniyappa et
al. [20]; USA
Crossover
a,b; 31 g/d cocoa; 900 mg
polyphenols;
51.0 yr; 20/20 Cocoa: 141 (13)/139 (9); Cocoa: 91 (13)
88 (9);
High flavanol
cocoa/low flavanol
drink
14 d Control: 28 mg 33.2 Control: 141 (13)/140
(9)
Control: 91 (13)/87 (9)
Davison et al.
(nonexercise
arm) [21];
Australia
Parallel; 300 ml drink
mix/d;
902 mg
flavanols;
44.9 yr; 12/11 Cocoa: 124 (10.4)/122.1
(ng);
Cocoa: 76 (6.2)/74.2
(ng);
High flavanol
cocoa/low flavanol
drink
84 d (12 wk); Control: 36 mg 33.6 Control: 124 (5.97)/
128.2 (ng)
Control: 77 (5.0)/79.8
(ng)
Davison
(exercise arm)
[21]; Australia
Parallel; 300 ml drink
mix/d;
902 mg
flavanols;
45.4 yr; 13/13 Cocoa: 126 (10.4)/127.1
(ng);
Cocoa: 78 (8.7)/77.5
(ng);
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High flavanol
cocoa/low flavanol
drink
84 d (12 wk) Control: 36 mg 33.4 Control: 121 (13.0)/
120.5 (ng)
Control: 74 (5.8)/73.8
(ng)
Shiina et al.
[22]; Japan
Parallel
a; 45 g/d 550 mg
polyphenols
29.8 yr; 20/19 Cocoa: 116.4 (12.7)/
121.0 (12.7);
Cocoa: 64.7 (11.7)/71.3
(10.8);
Dark/white
chocolate
14 d 22.6 Control: 121.6 (14.9)/
125.6 (11.4)
Control: 72.2 (13.8)/77.4
(11.6)
Ried et al.
(phase 1) [23];
Australia
Parallel; 50 g/d; 750 mg
polyphenols
53.1 yr; 11/10 Cocoa: 135.0 (12.5)/
133.1 (11.7)
c;
Cocoa: 83.6 (10.6)/84.5
(11.6);
Dark chocolate/
placebo pill
56 d (8 wk) 26.6 Control: 135.7 (12.4)/
130.8 (18.3)
c
Control: 77.8 (8.6)/77.3
(10.0)
Monagas et al.
[24]; Spain
Crossover; 40g/d + 250
skim milk;
control: 500 ml
skim milk
495 mg
polyphenols
69.7 yr; 42/42 Cocoa: 138 (26)/138
(16);
Cocoa: 84 (13)/82 (13);
Cocoa powder in
milk/milk only
28 d 27.6 Control: 138 (26)/135
(24)
Control: 84 (13)/81 (13)
a7-day cocoa/flavanol-free run-in period.
b7-day washout period before crossover.
cMedian.
BMI, body mass index; DBP, diastolic blood pressure; g/d, grams per day; mg; milligrams; ml, millilitre; N, number of participants; ng, not given; SBP, systolic
blood pressure; SD, standard deviation; yr, years; wk, weeks
Table 2 Characteristics of trials excluded from the meta-analysis
Trial; location Study design; treatment/
control groups
Dosage;
duration
Active ingredients
per daily dosage
Mean age;
mean BMI
N
treatment/
control
Reason for exclusion
Grassi et al. [19];
Italy
Crossover
a,c 100 g/d 500 mg polyphenols 33.9 yr; 15/15 Same population and protocol
as studied in Grassi et al. [11]
Dark/white chocolate 15 d 22.6
Allen et al. [34],
Erdman et al. [35];
USA
Crossover
b; 22g/d Not reported 44.7 yr; 44/44 No cocoa-free control group
Chocolate + plant sterols/
chocolate + no plant
sterols
28 d (4 wk) 27.8
Balzer et al. [36];
USA
Parallel; 3 drink mix/d 963 mg flavanols; 63.8 yr; 21/20 No mean SBP/DBP (SD) reported
High/low-flavanol drink 30 d (4 wk) control: 75 mg
flavanols
32.1
Faridi et al. [37];
USA
Crossover
a,c; 74 g bar with
22 g cocoa/d;
821 mg flavanols 53 yr; 44/44 Duration < 2 wk
Dark chocolate/placebo
bar
Single dose, 1
d
30
Ried et al. (phase 2)
[23]; Australia
Crossover
d; 50 g/d;
control: 1
capsule/d;
750 mg
polyphenols;
53.1 yr; 26/26 Crossover of two active
treatment groups, no true
control group
Dark chocolate/Tomato
extract capsules
56 days (8
wks)
control: tomato
extract (15 mg
lycopene)
26.6
Almoosawi et al.
[38]; UK
Crossover
a,c; 20 g/d; 1000 mg
polyphenols;
31 yr; 14/14 Two dosages, no true control
group
Dark chocolate dosage 1/
dosage 2
14 days control: 500 mg 27.7
a7-day cocoa/flavanol-free run-in period.
b2-week run-in period.
c7-day washout period before crossover.
d4-week washout period.
For abbreviations, see Table 1 footnote.
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adequately randomised; double-blinding was achieved in
five trial arms using low-flavanol-containing products as
control [11,15,20,21]. All but three trial arms [15,22,24]
assessed blood pressure as the primary outcome mea-
sure, and 12 of the 15 trial arms had a participant attri-
tion of less than 20% [10,11,13,15-18,22-24] (Table 3).
Eight trial arms used a parallel study design
[11,15-17,21-23], and seven study arms used a crossover
design [10,12,13,18,20,24]. All but two [12,24] of the
seven crossover trials incorporated a washout period of
7 days between the alternate treatment period. In eight
trials the intervention period was 2 weeks (14 or 15
days) [10-13,18,20,22], while longer intervention periods
were trialled in seven studies (range 4-18 weeks)
[15-17,21,23,24]. Eight trials employed a 7-day run-in
period before commencing with the treatments
[10,13,16-18,20,22] (Table 1).
Polyphenol content varied widely between the trials
(range 30-1008 mg/day, Table 1). Although authors
labelled the active ingredient in chocolate with a variety
of terms (polyphenol, flavanol, proanthocyanidin, epica-
techin and catechin), we are reasonably confident that
the reported dosages of total polyphenol or measured
derivates are comparable. There is some confusion in
the literature about the correct labelling of the vasoac-
tive chemical components in cocoa, and terms are often
used interchangeably and sometimes incorrectly.
Table 3 Quality assessment of trials included in the meta-analysis
Trial ID Total
score
Blinding Outcome measure:
blood pressure
Loss to
follow-up
Funding source Compliance; other
chocolate diary
Scores
given
1: choc + control blinded 1: Primary 1: < 20% 1: Sponsor not involved in
data collection, analysis
1: Compl assessed; no sign
diff between groups
0.5: control blinded 0.5: Secondary 0: ≥ 20% 0: Sponsor involved 1: Compl assessed, sign diff
included in analysis
0: No blinding 0: Compl not assessed
Taubert
et al. [10]
4 0: dark/white 1 1: none 1 1
Murphy
et al. [15]
3.5 1: cocoa tablets 0.5 1: 9.5% (4
of 42)
0: supported by Mars 1: tablet count, 7 day
weight food records x2
Engler et al.
[11]
5 1: flav bar matched 1 1: none 1 1
Fraga et al.
[12]
2.5 0: dark/white 1 1: 3.6% (1
of 28)
0: 3 authors from Mars 0.5: reported what
consumed, no diary
Grassi et al.
[13]
3.5 0: dark/white 1 1: none 0.5: unclear 1: daily diary
Grassi et al.
[13]
3.5 0: dark/white 1 1: none 0.5: unclear 1: daily diary
Taubert et
al. [16]
4 0: dark/white 1 1: none 1 1: food diary
Crews et al.
[17]
2.5 0.5: flav drink; > 50% assumed
correct group they were in
1 0.5: 11%
(11 of 101)
0.5: independent industry
research grant, supplier
0: not reported
Grassi et al.
[18]
3.5 0: dark/white 1 1: none 0.5: unclear 1: diary
Muniyappa
et al. [20]
3 1: flav drink; blinding assessed
ok
1 0: 31% (9
of 29)
1 0: not reported
Davison
et al. [21]
3 1: flav drink 1 0: 21% (14
of 65)
0: Mars Financial support 1: diet + background
exercise
Davison
et al. [21]
3 1: flav drink 1 0: 21% (14
of 65)
0: Mars Financial support 1: diet + background
exercise
Shiina et al.
[22]
2 0: dark/white 0 1: none 1 0
Ried et al.
[23]
4.5 0.5: control blinded 1 1: 8% (3 of
39)
1 1: diary
Monagas
et al. [24]
3.5 0: cocoa powder in milk/milk 0.5 1: none 1 1: diet monitoring (3-day
food questionnaires x3)
All 15 trial arms were adequately randomised.
Choc, chocolate; compl, compliance; flav, flavanol; sign diff, significant difference;
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polyphenol content analysis (high performance liquid
chromatography [39] and Folin-Ciocalteu method [40])
each measure both monomer (epicatechin and catechin)
and oligomer (proanthocyanidin) polyphenol compo-
nents. These polyphenol components belong to the fla-
vanols or flavanoids, which make up 99% of all
polyphenols in cocoa [41,42]. However, we were not
able to compare findings by method of polyphenol con-
tent analysis, as details were not available for all trials.
We collated information on age and weight/BMI
because age and BMI may influence responsiveness to
blood pressure treatment [43,44]. Mean age and BMI
varied substantially between trials: mean age ranged
between 18 and 70 years, and mean BMI was in the
overweight/obese category for 9 of the 15 trials (mean
BMI: < 25, n = 6; 25-30, n = 6; > 30, n = 3).
Meta-analysis
Meta-analysis of all 15 trial arms revealed a significant
blood pressure-reducing effect of cocoa/chocolate com-
pared with control (pooled mean SBP: -3.16 [95% CI,
-5.08, -1.23] mmHg, P = 0.001; pooled mean DBP: -2.02
[95% CI, -3.35, -0.69] mmHg, P = 0.003) (Figure 2). Het-
erogeneity between trials was high (SBP: I
2 = 74%; DBP:
I
2 = 62%), prompting subgroup meta-analysis by base-
line blood pressure as well as meta-regression and sensi-
tivity analyses.
We pooled trial arms with mean baseline SBP in the
hypertensive range (SBP ≥ 140 mmHg) and trial arms
with mean baseline SBP of < 140 mm Hg. While meta-
analysis of the SBP hypertensive subgroup remained
significant (SBPhyper: -5.02 [95% CI, -7.99, -2.05] mmHg;
P = 0.0009; Figure 3A), meta-analysis of the SBP normo-
tensive subgroup demonstrated no significant difference
in blood pressure reduction between the chocolate/
cocoa group and the control group (SBPnormo:- 1 . 5 6
[95% CI, -3.81, 0.68] mmHg, P = 0.17; Figure 3B). Het-
erogeneity remained high in the hypertensive subgroup,
but was reduced in the SBP normotensive subgroup
(SBPhyper: I
2 = 90%; SBPnormo: I
2 = 23%).
For subgroup analysis of diastolic blood pressure, we
pooled trial arms with mean baseline DBP in the hyper-
tensive and prehypertensive range (DBP ≥ 80 mmHg)
and trials with mean baseline DBP < 80 mm Hg. Three
of the six trial arms in the subgroup with DBP ≥ 80
mmHg reported mean DBP values at baseline in the
hypertensive range (≥ 90 mmHg) [13,18,20], while three
trials reported mean DBP at baseline in the prehyper-
tensive range (84-86 mmHg) [10,16,24].
Results of DBP subgroup analyses were similar to the
results of SBP subgroup analyses. While the DBP pre-/
hypertensive subgroup analysis remained significant
(DBPhyper: -2.73 [95% CI, -4.89, -0.58] mmHg, P =0 . 0 1 ;
I
2 = 79%; Figure 3C), DBP normotensive subgroup ana-
lysis demonstrated no significant difference between
chocolate and control groups (DBPnormo: -1.28 [95% CI,
-2.88, 0.33] mmHg, P = 0.12; I
2 = 24%; Figure 3D).
Funnel plots and Egger’s test indicated no publication
bias (Figure 4).
Meta-regression and sensitivity analysis
Five variables tested (dosage, duration, quality score, age
and BMI) did not show any significant association with
blood pressure outcomes in the meta-regression analy-
sis, while study design (parallel versus crossover) was
borderline significantly associated with BP outcome
(SBP: P =0 . 0 5 3 ;D B P :P = 0.060); and type of control
(flavanol-free control versus low-flavanol product as
control) was borderline significant for DBP (P = 0.052).
Subgroup analyses revealed reduced heterogeneity in
the subgroup including parallel trials, but high heteroge-
neity remained in the subgroup with crossover trials
(Table 4). Similarly, the subgroup including low-flavanol
products as control demonstrated lower heterogeneity
and no significant difference between treatment groups,
in contrast to the subgroup with flavanol-free unblinded
controls (Table 4).
However, the results of these subgroup analyses need
to be interpreted cautiously, as three of seven trial arms
with a crossover study design were conducted by the
same study team [13,18], and five of nine study arms
using a flavanol-free control were conducted by two
teams within similar population groups [10,13,16,18].
111 potentially relevant 
publications retrieved for 
abstract assessment  
+
19 potentially relevant 
unpublished studies 
identified on trial registries
21 potentially relevant trial 
arms (in 18 publications) 
 retrieved for detailed 
assessment 
15 trial arms (in 13 
publications) included in  
meta-analysis 
6 trial arms excluded from meta-
analysis because 
• 3 had no true control group 
￿ 1 duration < 14 days 
￿ 1 mean SBP/DBP + SD not available 
￿ 1 same population studied as in  
   another trial included in meta- 
   analysis 
93 publications excluded because  
￿ not an RCT, or study not assessing 
   the effects of cocoa on BP in humans 
+
19 unpublished registered trials   
excluded because 
￿ 13 not meeting inclusion criteria 
￿  3 not completed at time of meta- 
      analysis 
￿  3 completed but data not available 
Figure 1 Flow diagram of trial selection.
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be indirect predictors of BP outcome through other fac-
tors such as dietary habits of the study population.
Sensitivity analyses excluding trial [16], as this trial
used a notably lower dose and longer duration than the
other trials, did not change the results appreciably, with
one exception: A small but statistically significant differ-
ence between treatment groups in subgroup analyses of
trials with a parallel design shifted to a nonsignificant
effect when trial [16] was excluded (Table 4).
Discussion
Our meta-analysis including 15 trial arms demonstrated
a small but significant blood pressure-reducing effect of
flavanol-rich cocoa products compared with control
(mean BP change ± SE: SBP: -3.2 ± 1.9 mmHg, P =
0.001; DBP: -2.0 ± 1.3 mmHg, P = 0.003). These effect
sizes were smaller than in previous meta-analyses
including fewer trials (Taubert et al. (2007), 5 trials,
SBP: -4.7 ± 2.9 mmHg, P = 0.002; DBP: -2.8 ± 2.0
mmHg, P = 0.006, [9]; and Desch et al. (2010), 10 trials,
SBP: -4.5 ± 1.4 mmHg, P = 0.001, DBP: -2.5 ± 1.4
mmHg, P = 0.001, [14]).
In contrast to previous meta-analyses [9,14], subgroup
analyses in our larger meta-analysis suggested that there
is a difference in outcome dependent on baseline blood
pressure (hypertensive versus normotensive). While
meta-analyses of the hypertensive subgroups found
Figure 2 Meta-analysis of the effect of chocolate/cocoa on (A) systolic blood pressure or (B) diastolic blood pressure.N ,n u m b e ro f
participants; ΔSBP/ΔDBP, difference in mean SBP/DBP between start and end of intervention; SD, standard deviation; CI, confidence interval
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Page 8 of 11significant reductions (SBP: -5.0 ± 3.0 mmHg, P =
0.0009; DBP: -2.7 ± 2.2 mmHg, P = 0.01), analyses of
normotensive subgroups did not demonstrate a signifi-
cant reduction in blood pressure of flavanol-rich cocoa
products (SBP: -1.6 ± 2.3 mmHg, P = 0.17; DBP: -1.3 ±
1.6 mmHg, P = 0.12). These findings are in line with
meta-analyses of other nutritional supplements on blood
pressure, which similarly found that blood pressure was
significantly reduced in hypertensive subgroups but not
in the normotensive subgroups [30,45].
Heterogeneity was reduced satisfactorily in the normo-
tensive subgroups, indicating that trials in these sub-
group analyses are highly comparable and the meta-
analyses results can be interpreted with confidence. In
contrast, heterogeneity remained high in the hyperten-
sive subgroups, influenced greatly by one relatively small
study arm [13], which demonstrated a large blood pres-
sure reduction not matched by the other trials.
Therefore, effect sizes and levels of significance of the
subgroup meta-analyses of trials with (pre-)hypertensive
subjects at baseline should be interpreted more
cautiously.
The relatively modest but significant blood pressure-
lowering effect of cocoa in the hypertensive subgroup is
clinically relevant: a decline of 5 mmHg in systolic
blood pressure may reduce the risk of a cardiovascular
event by about 20% over 5 years [46]. Furthermore, the
effect of cocoa in a hypertensive population is compar-
able to other lifestyle modifications, such as moderate
physical activity (30 min/d) may reduce SBP by 4-
9 mmHg [5].
Meta-regression analyses suggested study design (par-
allel versus crossover) and type of control (flavanol-free
versus low-flavanol) to be significant predictors of blood
pressure outcome but failed to show any statistically sig-
nificant associations in the other variables tested. How-
ever, study design as well as type of control might be
indirect predictors, as about half the trials using a cross-
over design and white chocolate as flavanol-free control
were conducted by the same two teams and within simi-
lar study populations [10,13,16,18]. It is possible that
participants shared characteristics that contributed to
their responsiveness to cocoa products, such as local
dietary habits or genetic/ethnic disparity [47,48]. Inclu-
sion of trial location as a variable was impractical in our
meta-regression analysis; however, future research may
explore this further.
Furthermore, results of trials using flavanol-free con-
trols, including white chocolate or milk, might overesti-
mate the effect of the active treatment, owing to
potential bias of unblinded participants. Therefore,
r e l a t e ds u b g r o u pa n a l y s e sn e e dt ob ei n t e r p r e t e d
cautiously.
Meta-regression analysis did not suggest an associa-
tion between dosage, duration, quality of trials, age, BMI
and blood pressure outcome. However, inclusion of
future trials in meta-regression analysis might provide
further insight into predicting factors.
While regular consumption of flavanol-rich cocoa pro-
ducts may have a beneficial short-term effect in redu-
cing blood pressure in hypertensive individuals, the
practicability of chocolate or cocoa drinks as long-term
treatment is questionable. A recent small study by our
team investigating the acceptability of commercially
available chocolate bars as an alternative treatment to
capsules concluded that daily chocolate consumption for
blood pressure may not be an acceptable and practical
treatment option [23].
Conclusion
Our meta-analysis of 15 triala r m ss u g g e s t st h a td a r k
chocolate and flavanol-rich cocoa products are
Figure 4 Funnel plots of trials included in the meta-analysis for
(A) systolic blood pressure and (B) diastolic blood pressure. The
vertical line of Begg’s funnel plot represents the pooled mean effect
size, and the dotted lines represent the 95% confidence interval. P
values are derived from Egger’s test.
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Page 9 of 11superior to placebo in reducing systolic hypertension
and diastolic prehypertension. However, flavanol-rich
cocoa products did not significantly reduce mean
blood pressure below 140 mmHg systolic or 80 mmHg
diastolic. Additional trials of hypertensive populations
are needed to elucidate whether local dietary habits or
genetic factors influence the blood pressure-lowering
effect of cocoa.
List of Abbreviations
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